Health
Biotechnology
Pharmaceutical

Ionis Pharmaceuticals

$64.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.42 (-3.60%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!

About

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Employees
737
Headquarters
Carlsbad, California
Founded
1989
Market Cap
9.04B
Price-Earnings Ratio
26.13
Dividend Yield
0.00
Average Volume
1.11M
High Today
$68.74
Low Today
$63.80
Open Price
$67.63
Volume
1.29M
52 Week High
$86.58
52 Week Low
$40.91

Collections

Health
Biotechnology
Pharmaceutical
Therapy
Technology

News

Seeking AlphaMay 24

Ionis down 2% on FDA nod for Novartis gene therapy for SMA1

Ionis Pharmaceuticals (IONS -2.2% ) is under modest pressure on the heels of the FDA's OK of Novartis' gene therapy Zolgensma for spinal muscular atrophy Type 1 (SMA1). Ionis out-licensed nusinersen, branded as Spinraza, to Biogen. The FDA approved it in December 2016 for SMA....

34
Yahoo FinanceMay 14

Ionis Pharmaceuticals Is 40% of the Way There

Ionis Pharmaceuticals (NASDAQ: IONS) started the year off on a positive note, doubling revenue in the first quarter thanks to a large licensing payment from one of its partners.

189
Yahoo FinanceMay 9

Ionis Pharmaceuticals, Inc. Q1 2019 Earnings Call Transcript

Image source: The Motley Fool. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) Q1 2019 Earnings Call , 11:30 a.m. ET Operator Good morning and welcome to the Ionis Pharmaceuticals Q1 2019 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Vice President, Investor Relations to lead off the call. Please begin. Wade Walke -- Vice President, Investor Relations Thank you, Gary. Before we begin, I encourage everyone to ...

37

Earnings

-$0.17
$0.09
$0.36
$0.62
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.